GC

PLI’s Corporate Counsel Corner Provides Content Tailored for the In-House Legal Community

Retrieved on: 
Tuesday, April 9, 2024
GC, CLE, PLI, Ethics, Business, Research, Practising Law Institute, Publication, Lawyer, Curriculum, Leadership Academy

PLI’s Corporate Counsel Corner is a hub for legal, leadership, and industry content.

Key Points: 
  • PLI’s Corporate Counsel Corner is a hub for legal, leadership, and industry content.
  • Drawing on extensive research, including interviews with in-house counsel, surveys, and industry studies, the site was developed to meet these professionals’ specific needs.
  • “We recognize that lawyers who practice in-house as general counsel or in similar roles have unique professional development requirements,” says President Sharon L. Crane.
  • Practitioners also have direct access to timely, in-depth programs such as Hot Topics for In-House Counsel , Ethics for In-House Corporate Counsel , and many more, taught by expert faculty.

Cheer Holding Releases AI Animated Miniseries "Mystical Realm of Mountains and Seas"

Retrieved on: 
Tuesday, March 26, 2024
Cloud, GC, CHR, Polaris, Miniseries, Classic, Heart

BEIJING, March 26, 2024 (GLOBE NEWSWIRE) --  Cheer Holding, Inc. (NASDAQ: CHR) ("Cheer Holding," or the "Company"), a leading provider of advanced mobile internet infrastructure and platform services, today announced the release of its original AI animated miniseries, "Mystical Realm of Mountains and Seas” (the “Miniseries”).

Key Points: 
  • BEIJING, March 26, 2024 (GLOBE NEWSWIRE) --  Cheer Holding, Inc. (NASDAQ: CHR) ("Cheer Holding," or the "Company"), a leading provider of advanced mobile internet infrastructure and platform services, today announced the release of its original AI animated miniseries, "Mystical Realm of Mountains and Seas” (the “Miniseries”).
  • Delivered in captivating serialized seasons, each comprising 10 visually stunning episodes, this cinematic marvel offers a 2-minute immersive experience per episode.
  • Every frame is a testament to the revolutionary AI-generated technology pioneered by the Cheer Holding.
  • The grand unveiling of its original AI content creation marks a historic milestone for Cheer Holding, cementing the Company's position as an industry trailblazer in AI multimodal models and technology.

UnitedLex Continues Executive Team Expansion with Chief Operating Officer and EVP, Corporate & Commercial Services Appointments

Retrieved on: 
Tuesday, March 26, 2024
Bank of America, GC, EVP, Executive, SVP, Bank, Warner Bros. Discovery EMEA, Business development, Incident, Lawyer, Hinzmann, Analytics, Intellectual property, Corporation, Management

One of Ritter’s key mandates will be to further fortify the company’s operational infrastructure to continue to lead the market in technology enabled service delivery.

Key Points: 
  • One of Ritter’s key mandates will be to further fortify the company’s operational infrastructure to continue to lead the market in technology enabled service delivery.
  • Prior to UnitedLex, Ritter held various C-suite roles at Oliver Technology Corporation, Breakwater Solutions and DiscoverReady.
  • “The reputation of UnitedLex for providing groundbreaking solutions across multiple legal and business verticals has always intrigued me,” said Ritter.
  • Prior to joining UnitedLex, she has held numerous C-suite leadership roles with financial and legal services providers including Consilio, Cimplifi, and most recently Oliver Technology Corporation.

Green Check Partners with Order.co to Enhance Access to Cost-Saving Solutions for the Cannabis Industry

Retrieved on: 
Wednesday, March 20, 2024
GC, Growth, Partnership, Drug

"By enabling access to Order.co's innovative procurement platform through Green Check Connect, we're empowering cannabis businesses with essential tools to optimize their purchasing and payments processes," said Kevin Hart, CEO and founder of Green Check.

Key Points: 
  • "By enabling access to Order.co's innovative procurement platform through Green Check Connect, we're empowering cannabis businesses with essential tools to optimize their purchasing and payments processes," said Kevin Hart, CEO and founder of Green Check.
  • "Together with Green Check, Order.co is poised to make a substantial difference in the operational efficiency and financial health of cannabis businesses.
  • "We are really excited to partner with Green Check and offer Order.co via Green Check Connect.
  • To learn more about Green Check and its industry-leading business and financial services marketplace, visit greencheckverified.com .

Green Check Named “Best RegTech Company” by Fintech Breakthrough Awards and “Leading Pioneer in Cannabis Banking Solutions” by Commercial Cannabis Awards

Retrieved on: 
Thursday, March 14, 2024
GC, Software as a service, Growth, Fintech, Recognition, Global Health, Regulatory technology, Cannabis, Drug

GC was named "Best RegTech Company" in 2024 by Fintech Breakthrough Awards and a “Leading Pioneer in Cannabis Banking Solutions” by Global Health and Pharma’s 2023 Commercial Cannabis Awards .

Key Points: 
  • GC was named "Best RegTech Company" in 2024 by Fintech Breakthrough Awards and a “Leading Pioneer in Cannabis Banking Solutions” by Global Health and Pharma’s 2023 Commercial Cannabis Awards .
  • Recognition from Fintech Breakthrough and the Commercial Cannabis Awards underscore GC's pivotal role in expanding access to necessary financial and business solutions for cannabis-related businesses (CRBs), while ensuring financial institutions are equipped with the tools to confidently, compliantly and profitably serve CRBs.
  • “Green Check is at the center of cannabis and fintech, and these latest accolades highlight that synergy,” said Kevin Hart, founder and CEO of Green Check.
  • “Green Check is revolutionizing how financial institutions work with the cannabis market,” said Steve Johansson, managing director at FinTech Breakthrough.

ConCntric Streamlines Construction Procurement with BuildingConnected Integration

Retrieved on: 
Wednesday, March 13, 2024
Cloud, GC, Construction, Risk, SAN, Software

The entire bid package generated in ConCntric then syncs into BuildingConnected to distribute to subcontractors.

Key Points: 
  • The entire bid package generated in ConCntric then syncs into BuildingConnected to distribute to subcontractors.
  • Finally, the awarded values from BuildingConnected sync back into ConCntric to track the planned versus actual costs.
  • This integration specifically targets the procurement phase, aiming to streamline the often manual and disjointed processes prevalent in the industry.
  • ConCntric’s integration with BuildingConnected further solidifies their commitment to transforming preconstruction processes, setting a new standard for efficiency and effectiveness in the built world.

InnoCare Releases 2023 Results and Business Highlights

Retrieved on: 
Thursday, March 28, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, QD, Tafasitamab, Patient, B-cell lymphoma, NDA, SLE, POC, IND, Clinical trial, Bone marrow, IKZF1, Phase, Therapy, IGA, MCD, Dexamethasone, MCL, Neuromyelitis optica spectrum disorder, IKZF3, AML, NMOSD, Outline of health sciences, DLT, Cancer, Autoimmune disease, Safety, TYK2, HSA, NRDL, BLA, Follicular lymphoma, Food, GC, Development, Multiple sclerosis, PD, CRBN, Public, Gordon Ramsay's Bank Balance, Multiple myeloma, ITP, BCL2, Leukemia, Cmax, Gadolinium, HKEX, SRI, AAD, Proteinuria, DLBCL, Glucocorticoid, IVIG, Loss, European Hematology Association, American Academy, EHA, Lenalidomide, NHL, Non-Hodgkin lymphoma, CCR8, US FDA, BTK, NRS, Pharmaceutical industry

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.

Key Points: 
  • InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.
  • In 2023, InnoCare has continued to advance its robust pipeline across various clinical stages, continuously unleashing the power of innovation to meet unmet medical needs.
  • In June 2023, the ITP Phase II result was orally presented at the European Hematology Association (EHA) 2023 Hybrid Congress.
  • InnoCare was approved by the Hong Kong Stock Exchange to remove "B" from the stock code from May 12, 2023.

Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Pharmaceutical, Health, Research, A4, GC, Congenital adrenal hyperplasia, Administration, PCOS, P-value, GCS, Patient, Cash, Șaeș, Spruce, Outline, CAH, Clinical trial, Safety, Hyperandrogenism, Polycystic ovary syndrome, ULN, Research and development, Food, FDA, Pharmaceutical industry

(Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2023 and provided corporate updates.

Key Points: 
  • (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2023 and provided corporate updates.
  • “We are grateful to all the patients, families, study team and investigators who supported the CAHmelia-203 clinical trial,” said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, Spruce Biosciences.
  • Non-cash stock-based compensation expense for the year ended December 31, 2023 was $4.6 million compared to $3.6 million in 2022.
  • Net Loss: Net loss for the year ended December 31, 2023 was $47.9 million compared to $46.2 million in 2022.

Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Pharmaceutical, Health, GC, Obesity, Endocrinology, Clinical professor, Associate, Risk, Patient, GCS, Mayo Clinic, Androgen, Șaeș, CAH, Endocrine system, Safety, Workforce, Medical director, ACTH, Pharmaceutical industry

Preliminary pharmacokinetic analysis suggests that tildacerfont is cleared more rapidly in children than in adult CAH patients.

Key Points: 
  • Preliminary pharmacokinetic analysis suggests that tildacerfont is cleared more rapidly in children than in adult CAH patients.
  • 70% of patients with elevated baseline A4 values (16 of 23 patients) demonstrated an A4 reduction at week 4.
  • “The CAHptain-205 study results demonstrate safety and tolerability in pediatric CAH patients with weight-adjusted tildacerfont doses up to 200mg daily.
  • An archived copy of the call will be available on the events section of the company’s investor relations website for approximately 90 days.

Li-Cycle Announces $75 Million Strategic Investment from Glencore

Retrieved on: 
Tuesday, March 12, 2024
Other Manufacturing, Environment, Technology, Sustainability, Alternative Energy, Manufacturing, Green Technology, Energy, Batteries, Recycling, Exercise, Convertible, Sale, Bank statement, Investment, Marketing, Transaction, PIK, Audit committee, Committee, Partnership, Minority, LON, VWAP, Multilateral, Person, GC, Date, Annual report, 8-K, Hub, Nickel, Ontario Securities Commission, Cobalt, Redemption, Security (finance)

Ajay Kochhar, Li-Cycle co-founder and CEO, commented: “We are pleased to secure an additional $75 million investment from Glencore, following Glencore’s June 2022 investment, to improve our liquidity position while we continue our ongoing comprehensive review process.

Key Points: 
  • Ajay Kochhar, Li-Cycle co-founder and CEO, commented: “We are pleased to secure an additional $75 million investment from Glencore, following Glencore’s June 2022 investment, to improve our liquidity position while we continue our ongoing comprehensive review process.
  • The SC engaged Moelis & Company LLC, a leading global investment bank (“Moelis”), as its financial advisor and placement agent.
  • As part of the partnership, Glencore previously made a $200 million investment in Li-Cycle in June 2022 through the purchase of a convertible note (the “Existing Note”).
  • The Glencore investment will result in Glencore purchasing from the Company a senior secured convertible note in the aggregate principal amount of $75 million.